World's Best Scientists 2026 revealed!
David A. Flockhart

David A. Flockhart

D-Index & Metrics

Medicine

D-Index
93
Citations
30272
World Ranking
10929
National Ranking
5623

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

David A. Flockhart was affiliated with Indiana University in the United States. Their research contributions focused primarily on pharmacology, toxicology, pharmaceutics, medicine, and biochemistry, genetics and molecular biology. The scientist worked mainly within subfields such as pharmacology, biochemistry, pediatrics, perinatology and child health, endocrinology, diabetes and metabolism, and genetics.

Their scholarly work covered topics related to pharmacogenetics and drug metabolism, eicosanoids and hypertension pharmacology, pharmaceutical studies and practices, pharmacological effects and toxicity studies, hormonal regulation and hypertension, estrogen and related hormone effects, and inflammatory mediators and NSAID effects.

Among the research outputs were four papers published in UNC Libraries in 2020. These papers included:

  • In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles (2020, UNC Libraries)
  • Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study (2020, UNC Libraries)
  • Creating and evaluating genetic tests predictive of drug response (2020, UNC Libraries)
  • Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (2020, UNC Libraries)

Frequent collaborators included Howard L. McLeod, Christine M. Walko, Karen E. Weck, Oludamilola Olajide, and Rachel Raab, with whom David A. Flockhart coauthored multiple studies. Most of their works were published in a single primary venue, UNC Libraries.

David A. Flockhart was recognized as a member of the Association of American Physicians, an indication of their standing within the medical research community.

Best Publications

  • CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

    Yan Jin;Zeruesenay Desta;Vered Stearns;Bryan Ward

  • Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

    Zeruesenay Desta;Xiaojiong Zhao;Jae Gook Shin;David A. Flockhart

  • Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

    Vered Stearns;Michael D. Johnson;James M. Rae;James M. Rae;Alan Morocho

  • Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

    Matthew P. Goetz;James M. Rae;Vera J. Suman;Stephanie L. Safgren

  • Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

    Bryan P. Schneider;Molin Wang;Milan Radovich;George W. Sledge

  • Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

    Zeruesenay Desta;Bryan A. Ward;Nadia V. Soukhova;David A. Flockhart

  • The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

    Bryan A. Ward;J. Christopher Gorski;David R. Jones;Stephen D. Hall

  • The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

    Matthew P. Goetz;Stacey K. Knox;Vera J. Suman;James M. Rae

  • Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

    Silvana Borges;Zeruesenay Desta;Lang Li;Todd C Skaar

  • Pharmacological Characterization of 4-hydroxy- N -desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

    Michael D. Johnson;Hong Zuo;Kyung Hoon Lee;Joseph P. Trebley

  • Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase.

    Corbin Jd;Sugden Ph;West L;Flockhart Da

  • Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges

    Russell A. Wilke;Debbie W. Lin;Dan M. Roden;Paul B. Watkins

  • Rifampin Is a Selective, Pleiotropic Inducer of Drug Metabolism Genes in Human Hepatocytes: Studies with cDNA and Oligonucleotide Expression Arrays

    James M. Rae;Michael D. Johnson;Marc E. Lippman;David A. Flockhart

  • Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

    N. Lynn Henry;Faouzi Azzouz;Zereunesay Desta;Lang Li

  • Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications

    Stephen Bernard;Kathleen A. Neville;Anne T. Nguyen;David A. Flockhart

  • Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

    Young Chai Lim;Zeruesenay Desta;David A. Flockhart;Todd C. Skaar

  • Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants.

    Jose E. Tanus-Santos;Mehul Desai;David A. Flockhart

  • Pharmacogenomics: Challenges and Opportunities

    Dan M. Roden;Russ B. Altman;Neal L. Benowitz;David A. Flockhart

  • The pharmacogenetics research network: from SNP discovery to clinical drug response.

    K M Giacomini;C M Brett;R B Altman;N L Benowitz

  • Inhibition of IL-12 production by thalidomide.

    David R. Moller;Maria Wysocka;Brian M. Greenlee;Xiaojing Ma

Frequent Co-Authors

Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
Vered Stearns
Vered Stearns Johns Hopkins University
Yusuke Nakamura
Yusuke Nakamura National Institutes of Biomedical Innovation, Health and Nutrition
Matthew P. Goetz
Matthew P. Goetz Mayo Clinic
Howard L. McLeod
Howard L. McLeod Utah Tech University
Steffi Oesterreich
Steffi Oesterreich University of Pittsburgh
Russ B. Altman
Russ B. Altman Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up diverse career opportunities in the broader healthcare field. For students seeking alternatives to the traditional MD path, there are numerous accredited online programs that offer flexibility, affordability, and strong job prospects.

Those interested in pharmaceutical work may consider online pharmacy schools, which provide the necessary knowledge and credentials to become a licensed pharmacist. Alternatively, for students attracted to data and technology, rhit programs online can lead to in-demand roles in health information management and data security.

Administrative healthcare careers are also rapidly growing. With medical billing and coding online courses, students can gain the essential expertise needed for medical office roles, often from the comfort of home. Nursing remains a critical component of the healthcare system, and cheapest nurse practitioner programs make advanced clinical education more accessible than ever.

These online options offer flexible, respected pathways into the healthcare industry—perfect for those seeking a rewarding career without following the traditional route to medicine.

Best Scientists Citing David A. Flockhart